![]() Consequently, it is important to find therapeutics that can preferentially target these cells. We have demonstrated that the PSA-/lo PCa cell population harbors self-renewing prostate cancer stem cells (PCSCs) that are intrinsically resistant to ADT and can long-term propagate tumors, mediate recurrence, and serve as a cell-of-origin for CRPC (Cell Stem Cell, 2012 Oncotarget, 2015 Clin Cancer Res, 2016 Oncotarget 2016). Both untreated advanced PCa and CRPC are enriched in phenotypically undifferentiated PCa cell populations that expresses little or no prostate specific antigen (i.e., PSA-/lo). Despite an initial response, the majority of patients relapse resulting in castration-resistant prostate cancer (CRPC). Scientific Tracks Abstracts : J Med Oncl TherĪndrogen deprivation therapy (ADT) is the mainstay treatment for patients with advanced prostate cancer (PCa). ![]() Tongji University School of Medicine, China The University of Texas MD Anderson Cancer Center, USA ![]() University of Texas Health Science Center at Houston, USA Kiera Rycaj, John Moore, Xin Liu, Mikhail G Kolonin and Tang DG PHAGE DISPLAY LIBRARY SCREENING IDENTIFIES NOVEL BINDING PEPTIDES THAT PREFERE NTIALLY TARGET CASTRATION-RESISTANT PSA-/lo PROSTATE CANCER STEM CELLSġ1 th International Conference on Cancer Stem Cells and Oncology Research
0 Comments
Leave a Reply. |